15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand

      abstract
      1 , , 1 , 2 , 3 , 3 , 1 , 3 , 4 , 4
      Retrovirology
      BioMed Central
      AIDS Vaccine 2009
      19–22 October 2009

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background Data collected for a clinical trial should have errors at the minimum level; high rates of data discrepancy or incompleteness may affect validity of the trial conclusions. Proof of data quality is also an essential requirement for regulatory bodies. The study objectives were to present best practices and assess data management process and data quality of the largest trial. Methods Data were extracted from phase III vaccine trial conducted among Thai adults. This study began in 2003 and closed out in July 2009. To meet scientific and ethical standards, good clinical data management practice (GCDMP) had been implemented to obtain high quality data. Results The CDM process was prepared at the trial initiation. The systems were routinely validated; the data, IT and quality assurance staff were trained to complete their responsibilities effectively. The data collected in this study met CDM metrics in both quantity and quality. In this study, 16,402 healthy volunteers enrolled into the study for 3 years follow-up. Of the 1,148,839 case record forms (CRFs), there were 82,502 QCs composed of 21% missing data and 22% inconsistent values; time to QC resolved ranged from 7 to 11 days. There were 2,691 events of protocol deviation captured and all get resolved timely. Data coding was done for 27,714 AEs and 2,925 SAEs using MedDRA; the AE and SAE databases were reconciled prior to the study closure. Source document and CRFs were 100% verified; the accuracy assessment for efficacy and safety data was performed before declaration of clean databases for final analysis. Conclusion The trial had been conducted under GCDMP; best practices in quality assurance and quality control was crucial in making this trial analysis datasets valid and reliable. The results of this study were scientifically sound and in compliance with the protocol and all aspects of trial conduct.

          Related collections

          Author and article information

          Conference
          Retrovirology
          Retrovirology
          BioMed Central
          1742-4690
          2009
          22 October 2009
          : 6
          : Suppl 3
          : P215
          Affiliations
          [1 ]Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
          [2 ]Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
          [3 ]Department of Disease Control, Ministry of Public Health, Nontaburi, Thailand
          [4 ]US Military HIV Research Program, Rockville, MD, USA
          Article
          1742-4690-6-S3-P215
          10.1186/1742-4690-6-S3-P215
          2767710
          bc81881a-dd09-4eff-83a8-7bb6d0b61f0a
          Copyright © 2009 Kaewkungwal et al; licensee BioMed Central Ltd.
          AIDS Vaccine 2009
          Paris, France
          19–22 October 2009
          History
          Categories
          Poster Presentation

          Microbiology & Virology
          Microbiology & Virology

          Comments

          Comment on this article